SLC22A14 and hepatocellular carcinoma: As shown in Figure 3, VEGF-A, HIF-1α, and ADH1A expression were significantly lower in HCC tissues from sorafenib-responsive patients (n = 20), whereas SLC22A14 expression was significantly higher.